| http://purl.uniprot.org/citations/33478111 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/33478111 | http://www.w3.org/2000/01/rdf-schema#comment | "Malignant melanoma is the most common lethal skin cancer and causes death in a short time when metastasized. Although BRAF inhibitors (BRAFi) have greatly improved the prognosis of BRAF-mutated melanoma, drug resistance is a major concern even when they are combined with MEK inhibitors. Alternative treatments for BRAFi-resistant melanoma are highly anticipated. Nectin cell adhesion molecule 4 (NECTIN4) is highly expressed and associated with progression in tumors. We aimed to investigate the role of NECTIN4 in melanoma and its potency as a therapeutic target using 126 melanoma samples and BRAFi-resistant cells. Immunohistochemically, most of the clinical samples expressed NECTIN4, at least in part. NECTIN4 was highly expressed in BRAF-mutated melanoma and its high expression was associated with disease-free survival. In BRAFi-resistant melanoma cells, NECTIN4 and the PI3K/Akt pathway were upregulated, along with the acquisition of BRAFi resistance. Monomethyl auristatin E, a cytotoxic part of NECTIN4-targeted antibody-drug conjugate, was effective for BRAF-mutated or BRAFi-resistant melanoma cells. NECTIN4 inhibition increased the sensitivity of BRAFi-resistant cells to BRAFi and induced apoptosis. In conclusion, we revealed the expression and roles of NECTIN4 in melanoma. Targeted therapies against NECTIN4 can be a novel treatment strategy for melanoma, even after the acquisition of BRAFi resistance."xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.org/dc/terms/identifier | "doi:10.3390/ijms22020976"xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/author | "Ito T."xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/author | "Tanaka Y."xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/author | "Murata M."xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/author | "Shen C.H."xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/author | "Furue M."xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/date | "2021"xsd:gYear |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/name | "Int J Mol Sci"xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/pages | "976"xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/title | "NECTIN4: A Novel Therapeutic Target for Melanoma."xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://purl.uniprot.org/core/volume | "22"xsd:string |
| http://purl.uniprot.org/citations/33478111 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/33478111 |
| http://purl.uniprot.org/citations/33478111 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/33478111 |
| http://purl.uniprot.org/uniprot/#_B4DWD4-mappedCitation-33478111 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33478111 |
| http://purl.uniprot.org/uniprot/#_K4PZ75-mappedCitation-33478111 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33478111 |
| http://purl.uniprot.org/uniprot/#_Q9HBN2-mappedCitation-33478111 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33478111 |
| http://purl.uniprot.org/uniprot/#_Q96NY8-mappedCitation-33478111 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33478111 |
| http://purl.uniprot.org/uniprot/B4DWD4 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/33478111 |
| http://purl.uniprot.org/uniprot/K4PZ75 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/33478111 |
| http://purl.uniprot.org/uniprot/Q96NY8 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/33478111 |
| http://purl.uniprot.org/uniprot/Q9HBN2 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/33478111 |